Do anti-amyloid beta protein antibody cross reactivities confound Alzheimer disease research?

详细信息    查看全文

• 作者：Sally Hunter ; Carol Brayne
• 关键词：Alzheimer disease ; Amyloid beta protein ; Amyloid precursor protein ; Antibody ; Cross reactivity ; Experimental design
• 刊名：Journal of Negative Results in BioMedicine
• 出版年：2017
• 出版时间：December 2017
• 年：2017
• 卷：16
• 期：1
• 全文大小：712KB
• 刊物主题：Biomedicine, general; Medicine/Public Health, general;
• 出版者：BioMed Central
• ISSN：1477-5751
• 卷排序：16

文摘

BackgroundAlzheimer disease (AD) research has focussed mainly on the amyloid beta protein (Aβ). However, many Aβ-and P3-type peptides derived from the amyloid precursor protein (APP) and peptides thought to derive from Aβ catabolism share sequence homology. Additionally, conformations can change dependent on aggregation state and solubility leading to significant uncertainty relating to interpretations of immunoreactivity with antibodies raised against Aβ. We review evidence relating to the reactivities of commonly used antibodies including 6F3D, 6E10 and 4G8 and evaluate their reactivity profiles with respect to AD diagnosis and research.